Finder's Pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Champions Oncology is a biotechnology business based in the US. Champions Oncology stocks (CSBR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.54 – an increase of 2.24% over the previous week. Champions Oncology employs 194 staff and has a trailing 12-month revenue of around $46.8 million.
|Latest market close||$7.76|
|52-week range||$6.81 - $11.25|
|50-day moving average||$7.54|
|200-day moving average||$8.47|
|Wall St. target price||$14.67|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.01|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2022-06-21)||2.24%|
|1 month (2022-05-24)||5.15%|
|3 months (2022-03-24)||-2.76%|
|6 months (2021-12-24)||N/A|
|1 year (2021-06-28)||-26.72%|
|2 years (2020-06-26)||-13.59%|
|3 years (2019-06-28)||7.83|
|5 years (2017-06-28)||173.24%|
Valuing Champions Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Champions Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Champions Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 861x. In other words, Champions Oncology shares trade at around 861x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Champions Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 million.
The EBITDA is a measure of a Champions Oncology's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$46.8 million|
|Operating margin TTM||0.58%|
|Gross profit TTM||$19.6 million|
|Return on assets TTM||0.57%|
|Return on equity TTM||2.56%|
|Market capitalisation||$104.8 million|
TTM: trailing 12 months
We're not expecting Champions Oncology to pay a dividend over the next 12 months.
Champions Oncology's shares were split on a 1:12 basis on 11 August 2015. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Champions Oncology shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Champions Oncology shares which in turn could have impacted Champions Oncology's share price.
Over the last 12 months, Champions Oncology's shares have ranged in value from as little as $6.81 up to $11.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Champions Oncology's is 1.0272. This would suggest that Champions Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc.
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.Read more…
Here are some investment ideas that could do well despite rising interest rates.Read more…
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.
Everything we know about the Onfolio Holdings IPO plus information on how to buy in.
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.